Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology
Condition(s):LAD1Last Updated:August 8, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):LAD1Last Updated:August 8, 2023Recruiting
Condition(s):Leukocyte Adhesion Deficiency, Type IILast Updated:January 25, 2019Completed
Condition(s):Leukocyte Adhesion Deficiency SyndromeLast Updated:March 4, 2008Completed
Condition(s):Leukocyte Adhesion Defect – Type ILast Updated:December 7, 2021Withdrawn
Condition(s):Leukocyte Adhesion DeficiencyLast Updated:February 28, 2024Enrolling by invitation
Condition(s):Leukocyte Adhesion DeficiencyLast Updated:March 5, 2024Recruiting
Condition(s):Leukocyte Adhesion DeficiencyLast Updated:March 5, 2024Recruiting
Condition(s):Leukocyte Adhesion Defect – Type ILast Updated:November 15, 2023Completed
Condition(s):Leukocyte-Adhesion Deficiency SyndromeLast Updated:March 4, 2008Completed
Condition(s):Leukocyte Adhesion Deficiency SyndromeLast Updated:July 2, 2017Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.